Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
13 must-see moon events in 2026: Eclipses, supermoons, conjunctions and more - 2Venus shines at its best in spring and summer 2026 — here's what to look for
- 3Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- 4Chemical leak in Oklahoma forces evacuations and leaves many ill
- 5Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
- How to watch 'A Charlie Brown Christmas' for less with this Apple TV Black Friday deal
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- Russia Creates New Military Branch Dedicated To Drone Warfare
- The Best Music Collections of the 10 years
- Figure out How to Pick the Right Toothbrush for You
- Nuno Loureiro, MIT physicist, fatally shot at home; police investigate
- Moldova says Russian drones violated airspace
- Figure out how to Use Your Brain research Degree in the Gig Market
- Enormous Credit And All that You Really want To Be aware
